BC602 / Dragon Boat Biopharmaceutical - LARVOL DELTA

BC602: An IND-enabling stage LGR5x EGFR bispecific antibody with superior anti-tumor efficacy in mouse CDX and PDX models (AACR 2026) - "Non-clinical GLP PK and toxicity studies of BC602 and 200L scale clinical batch production are ongoing. IND filing is expected in 2026 Q3, and the planned indications include cancer types that overexpress both EGFR and LGR5 including HNSCC and CRC."

Bispecific • Preclinical • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • LGR5